drugs, including a diuretic). A subset of patients (n=129) is being followed to 3 years post-RDN (35 consented to laboratory assessments to 3 years). The primary endpoint is change in office-based BP from baseline. Data collection includes office-based BP measurement every 6 months, renal function, electrolytes, and medication usage.

Results: A total of 34 patients have reached the 3 year follow-up time point (9 with labs). Baseline BP was 175/98±12/11 mmHg. Mean SBP change post-RDN was -18.0±16.6 mm Hg at 1 month, -28.4 ± 17.6 mm Hg at 6 months, -27.6 ± 16.3 mm Hg at 2 years and -31.3 ± 14.9 mm Hg at 3 years. Medication usage remained similar to baseline with 35% aldosterone antagonist, 85% beta blocker and 82% calcium channel blocker use at baseline and at 3 years; diuretic use 91% and 88%, angiotensin receptor antagonists 71% and 76%, and ACE inhibitors 50% and 59% at baseline and 3 years, respectively. At 3 years estimated glomerular filtration rates (eGFR) declined by -13.2±12.1 from a baseline of 82.2±16.1 mL/min/m^2.

Conclusions: Among patients with full 3 year follow-up, RDN results in significant, sustained lowering of SBP in patients with treatment-resistant hypertension and a baseline SBP > 160 mm Hg. Antihypertensive medication usage was similar at baseline and 3 years.

CRT-4

Multi-center, First-in-man Evaluation Of The Myolimus-eluting Bioresorbable Coronary Scaffold: 6-month Clinical And Imaging Results

Stefan Verheye,[1] Mark Webster,[2] Jim Stewart,[3] Alexandre Abizaid,[4] Ricardo Costa,[5] J. Ribamar Costa,[5] John Yan,[6] Vinayak Bhat,[6] Sara Toyloy,[6] Lynn Morrison,[6] John Ormiston[3]

[1]ZNA Middelhiem, Antwerpen, Belgium [2]Auckland City Hospital, Auckland, New Zealand [3]Mercy Angiography Unit, Auckland, New Zealand [4]Instituto Dante Pazzanese, Sao Paulo, Brazil [5]Cardiovascular Research Center, Sao Paulo, Brazil [6]Elixir Medical Corporation, Sunnyvale, CA

Aims: To evaluate the clinical safety and effectiveness of the DESolve™ Myolimus-Eluting Bioresorbable Coronary Scaffold (BCSS)in patients with single de novo native coronary artery lesions through clinical endpoints and multiple imaging modalities.

Methods and Results: Background: The DESolve BCSS is a novel drug eluting device that combines a PLLA-based scaffold coated with a bioresorbable polylactide-based polymer and the drug Myolimus. Myolimus, a macrocyclic lactone mTOR inhibitor has demonstrated potent anti-proliferative properties in two First-in-Man (FIM) trials using Elixir's metallic Myolimus-eluting coronary stents. Drug dose is 3 mcg per mm of scaffold length; the same dose used in the FIM studies. Sixteen patients with single, de novo coronary artery lesions were enrolled in this prospective, multi-center, single-arm FIM study. One patient did not receive a study stent and was deregistered. The 15 remaining patients are being analysed for multiple clinical endpoints: Device and Procedure Success; Major Adverse Cardiac Events (MACE), a composite endpoint of cardiac death, target vessel MI, and clinically-indicated target lesion revascularization (CI-TLR); clinically-indicated Target Lesion and Target Vessel Revascularization, (CI-TVR) and stent thrombosis assessed at 1, 6 and 12 months and annually to 5 years. Multiple assessments by angiographic, IVUS and OCT at 6 months were completed. An additional analysis using multislice computed tomography (MSCT) will be completed at 12 and 24 months. At 6 months, the in-scaffold late lumen loss was 0.19 ± 0.19 by QCA, the % volume obstruction was 7.18 ± 3.37 by IVUS, and by OCT 98.68 ± 2.44% of struts were demonstrated as covered. There was one MACE event, a TLR, during the follow-up period. Detailed clinical and imaging results through 12 months will be presented.

Conclusion: The DESolve™ Myolimus-Eluting BCSS demonstrated both excellent safety and effectiveness in this FIM study, thus warranting further clinical evaluation of the novel technology in larger clinical studies. Detailed clinical and imaging results through 12 months will be presented.

CRT-5

Why Patients Presenting with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention and Treated with Prasugrel are Switching Back to Clopidogrel

Joshua P Loh, Lakshmana K Pendyala, Hironori Kitabata, Israel M Barbash, Danny Dvir, Salem M Badr, Sa'ar Minha, Rebecca Torguson, Lowell F Satler, Kenneth M Kent, William O Suddath, Augusto D Pichard, Ron Waksman
MedStar Washington Hospital Center, Washington, DC

Background: The reasons for switching from prasugrel back to clopidogrel after percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) are unclear, but are frequently practiced. The study aims to compare the characteristics and in-hospital outcomes of patients initially given prasugrel but was switched back to clopidogrel versus those who were continued on prasugrel on discharge.

Methods: The study included a cohort of 152 consecutive AMI patients who were first loaded with prasugrel and underwent PCI. Patients were categorized into switched therapy to clopidogrel on discharge (Switched, n=58) and continued therapy on prasugrel on discharge (Continued, n=94). Patient and procedural characteristics, as well as PCI-related complications and in-hospital outcomes were evaluated.

Results: Baseline demographics and procedural characteristics of both groups were similar. Patients who switched to clopidogrel on discharge had significantly longer hospital stay, and intensive care unit stay trended longer. Switched patients had significantly higher incidence of blood transfusions. Major bleeding, hematocrit drop, hematoma and urgent coronary artery bypass grafting (CABG) also trended higher in patients who switched therapy.

Concomitant coumadin therapy was significantly higher in the switched therapy group, whereas aspirin therapy was similar in both groups. No in-hospital mortality or myocardial infarction occurred in either groups (Table).

Conclusion: In-hospital bleeding complications requiring blood transfusion, need for urgent CABG and concomitant coumadin therapy are the main reasons for switching of antiplatelet therapy from prasugrel to clopidogrel prior to discharge.

In-hospital outcomes and concomitant therapy on discharge

	Switched to clopidogrel (n=58)	Continued on prasugrel (n=94)	P value
Length of stay in intensive care unit (days)	1.1 ± 1.5	0.7 ± 1.0	0.051
Overall hospital length of stay (days)	4.3 ± 4.3	2.9 ± 1.8	0.021
Death or Q wave myocardial infarction	0	0	-
Coronary artery bypass grafting	3 (5.2%)	0	0.054
Blood transfusion	7 (12.1%)	0	<0.001
Major bleeding	4 (6.9%)	1 (1.1%)	0.070
Hematocrit drop >15%	5 (8.5%)	1 (1.1%)	0.060
Hematoma	4 (6.9%)	1 (1.1%)	0.070
Concomitant coumadin therapy on discharge	10 (17.2%)	5 (5.3%)	0.017

CRT-6

Safety and Efficacy of Ultrasound-guided Thrombin Injections at the 'Neck' of Pseudoaneurysms

Salem Badr, Hironori Kitabata, Israel Barbash, Saar minha, Lakshmana Pendyala, Jousha Loh, Rebecca Torguson, Fang Chen, William Suddath, Lowell Satler, Augusto Pichard, Ron Waksman, Nelson Bernardo
MedStar Washington Hospital Center, Washington, DC

Background: Thrombin injection has been the treatment of choice for iatrogenic arterial pseudoaneurysms (PSAs). However, certain morphological features of the PSA, i.e. neck width and length, occasionally precludes the use of this treatment option using the current recommended technique.

Methods: Between March 2008 and June 2012, 146 consecutive patients who underwent thrombin injection for post percutaneous coronary intervention related PSAs were retrospectively studied. The technique of injecting as superficial and as far from the PSA tract is compared with injecting at the 'neck' of the PSA.

Results (Table) Ninety-one patients had superficial thrombin injection (STI) and 55 patients had neck thrombin injection (NTI). Baseline characteristics were similar in both groups. At the time of injection, all patients were on dual antiplatelet therapy and 9.6% were on oral anti-coagulation therapy without significant difference between both groups.